These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34079087)

  • 1. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.
    Saraon P; Pathmanathan S; Snider J; Lyakisheva A; Wong V; Stagljar I
    Oncogene; 2021 Jun; 40(24):4079-4093. PubMed ID: 34079087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances of targeting receptor tyrosine kinases in cancer.
    Tomuleasa C; Tigu AB; Munteanu R; Moldovan CS; Kegyes D; Onaciu A; Gulei D; Ghiaur G; Einsele H; Croce CM
    Signal Transduct Target Ther; 2024 Aug; 9(1):201. PubMed ID: 39138146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinases and targeted cancer therapeutics.
    Takeuchi K; Ito F
    Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
    Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
    Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.
    Saigí M; Carcereny E; Morán T; Cucurull M; Domènech M; Hernandez A; Martinez-Cardús A; Pros E; Sanchez-Cespedes M
    Cancer Treat Rev; 2022 Sep; 109():102430. PubMed ID: 35777135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase inhibitors in cancer.
    Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
    Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review.
    Orrico KB
    J Oncol Pharm Pract; 2023 Jul; 29(5):1187-1195. PubMed ID: 36734129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
    Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
    BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteome-Wide Detection and Annotation of Receptor Tyrosine Kinases (RTKs): RTK-PRED and the TyReK Database.
    Filis G; Baltoumas FA; Spanogiannis G; Litou ZI; Iconomidou VA
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase receptors as attractive targets of cancer therapy.
    Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
    Bhattacharya P; Shetake NG; Pandey BN; Kumar A
    Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to drugs targeting receptor tyrosine kinases.
    Rosenzweig SA
    Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.